抗HBV-DC联合胸腺肽α1治疗e抗原阴性慢性乙型肝炎的初步临床研究  

Primary clinical research of anti-HBV-DC combined with thymosin α1 in the treatment of e antigennegative chronic hepatitis B

作　　者：柯成能 刘勇[1] 肖红刚 

机构地区：[1]南方医科大学东莞仁康医院内一科,523952

出　　处：《中国实用医药》2015年第17期49-51,共3页China Practical Medicine

摘　　要：目的探讨抗乙肝树突状细胞(HBV-DC)联合胸腺肽α1在e抗原阴性慢性乙型肝炎患者中的临床治疗效果。方法 80例e抗原阴性慢性乙型肝炎患者,随机分为两组,每组40例。对照组采用抗HBV-DC治疗,实验组联合胸腺肽α1治疗,比较两组治疗效果。结果实验组总有效率95.0%,明显高于对照组85.0%,差异有统计学意义(P<0.05);实验组谷草转氨酶(AST)指标、谷丙转氨酶(ALT)指标,低于对照组,差异有统计学意义(P<0.05)。结论 e抗原阴性慢性乙型肝炎发病率较高,临床上采用抗HBV-DC联合胸腺肽α1治疗效果理想,能够提高临床疗效,改善患者肝功能,值得推广。Objective To investigate the clinical effect of anti- hepatitis B dendritic cell（HBV-DC） combined with thymosin α1 in the treatment of e antigen-negative chronic hepatitis B. Methods A total of 80 patients with e antigen-negative chronic hepatitis B were randomly divided into two groups, with 40 cases in each group. Control group received anti-HBV-DC for treatment, and experimental group received anti-HBVDC combined with thymosin α1 for treatment. Curative effects of the two groups were compared. Results The experimental group had total effective rate as 95.0%, which was much higher than 85.0% of the control group, and their difference had statistical significance（P〈0.05）. The experimental group had lower levels of aspartate aminotransferase（AST） index and alanine aminotransferase（ALT） index than the control group, and their difference had statistical significance（P〈0.05）. Conclusion The morbidity of e antigen-negative chronic hepatitis B is high. Clinical treatment by anti-HBV-DC combined with thymosin α1 provides ideal effect in improving clinical effect and liver function. This method is worthy of promotion.

关 键 词：抗乙肝树突状细胞 胸腺肽Α1 E抗原阴性慢性乙型肝炎 治疗效果 

分 类 号：R512.62[医药卫生—内科学]